CEBPA and acute myeloid leukemia: Previous studies reported that GATA2mut, especially GATA2 ZF1 mutations [6, 25, 26], often coexist with CEBPA mutations, with an incidence of 18%–41% in non-M3 AML patients [1, 27, 28].